Takeaway
- Both holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (B-TUEP) are safe, minimally invasive surgical options for treating benign prostatic hyperplasia (BPH) in patients at high risk of bleeding because of anticoagulation (AC) or antiplatelet (AP) therapy.
Why this matters
- A significant number of patients who require surgery for BPH are receiving either AC or AP therapy.
Study design
- Researchers analyzed the health records of patients who underwent HoLEP and B-TUEP and were receiving AC or AP therapy or neither therapy (N=438; 100% white; HoLEP, 67.6%; B-TUEP, 32.4%).
- Funding: None.
Key results
- Patients in the HoLEP group with either AC or AP therapy required longer catheter maintenance and hospital stays (all P≤.01).
- Patients in the B-TUEP group with either AC or AP therapy had longer hospital stays (P=.03) and more complications (P=.001).
- Operative times and rates of postoperative complications were similar regardless of AC or AP therapy.
- Postoperative hemoglobin drop and 2-month International Prostate Symptoms Scores were similar regardless of therapy or surgical technique.
Limitations
- The study was retrospective and did not assess complications or functional outcomes >60 days after surgery.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started